Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$2.45MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kristen Fortney
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 61
- Beta
- 0.94
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 3.85
Financials
Revenue
$2.45M+68.9%Net Income
$-26.10MEBITDA
$-26.03MFree Cash Flow
$-19.59MEPS (diluted)
$-0.58Shares Outstanding (diluted)
44.84M+31.2%Operating Expenses
$31.78MCash & Debt
$318.75MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $8.99M | $-80.61M | $-2.24 |
| 2024 | $0.00 | $-71.11M | $-1.98 |
| 2023 | $0.00 | $-63.85M | $-1.87 |
| 2022 | $0.00 | $-39.72M | $-1.16 |
Valuation
BIOAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-4.76%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·25d ago·Neutral
BioAge Labs to Present at Upcoming Investor Conferences EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:
View source ↗ - Newsseekingalpha.com·34d ago·Positive
BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·41d ago·Positive
BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsglobenewswire.com·42d ago·Positive
…pment strategy in other NLRP3-driven retinal diseases, including geographic atrophy EMERYVILLE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge” or the “Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-10…
View source ↗ - Newsseekingalpha.com·45d ago·Neutral
…GE-102. BGE-102, a best-in-class NLRP3 inhibitor, achieved up to 98% IL-1β suppression and 86% median hsCRP reduction, with Phase 2 topline data expected in H2 2026. BIOA's diversified pipeline includes ophthalmology and apelin-APJ pathway programs, plus partnerships with Novartis and Eli Lilly, supporting long-term optionality.
View source ↗
Earnings
Thu, Nov 5(in 2 weeks)
Consensus estimate $-0.68 per share
Typical surprise +13.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.58 vs $-0.61beat
- Fri, May 8$-0.52 vs $-0.64beat
- Tue, Mar 24$-0.72 vs $-0.83beat
- Thu, Nov 6$-0.56 vs $-0.67beat
- Wed, Aug 6$-0.60 vs $-0.56miss
- Tue, May 6$-0.36 vs $-0.52beat
Estimates and results for BIOA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BIOA officers and directors.
- Bought
- $28.7m
- Sold
- $7.8m
7 trades
13 trades
- Barton Shanesold
- Barton Shanesold
- Rubin Paul Dsold
- Rubin Paul Dsold
- Rubin Paul Dsold
- Goldstein Dov A Mdsold
- Goldstein Dov A Mdsold
- Goldstein Dov A Mdsold
80 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BIOA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.